The Leprosy Watcher

Volume 16 | Issue 13 | 15 | Jun. 24, 2002 Previous | Next The Leprosy Watcher Armed with recent genomics data, Bill Levis ponders leprosy's immunological fork in the road--and awaits a government decision regarding his own career | By Tom Hollon Graphic: Marlene J. Viola Patients come to him by referral, dreading what they may hear after being poked and palpated and scrutinized by one puzzled

Written byTom Hollon
| 8 min read

Register for free to listen to this article
Listen with Speechify
0:00
8:00
Share

Patients come to him by referral, dreading what they may hear after being poked and palpated and scrutinized by one puzzled doctor after another, until someone wondered ominously--Leprosy?--and called William R. Levis at Bellevue Hospital in New York. It is gut-wrenching to be labeled a leper, a word that has shed little of its ancient stigma. Patients are grateful their condition has another name, Hansen disease, and if they ever risk telling someone what they have, they pray that person won't be the sort to look things up in a dictionary.

At least there is comfort in knowing that Levis is the very best. You won't end up deformed, not if he can do anything about it. "We cure them all," says Levis, who has been at this for 21 years, "but you want to cure them with no residual deformity." To do that takes experience: "You learn how to ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies